<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(2)</volume><submitter>Feng Y</submitter><pubmed_abstract>Recent studies revealed that CD39 was highly expressed in tumor-specific CD4&lt;sup>+&lt;/sup> tumor infiltrating lymphocytes (TILs). However, the divergent function of CD39&lt;sup>+&lt;/sup> T cells remains to be elucidated in colorectal cancer (CRC). In this study, T cells from CRC patients and tumor-bearing mice were isolated to evaluate the function of CD39 in T cells. We found that CD39 was elevated in intratumoral T cells from CRC patients, and negatively correlated with cytokine secretion capacity. T cell activation induced CD39 expression, and CD39&lt;sup>+&lt;/sup> T cells produced more IFN-γ in response to CRC tumor antigens. In addition, CD39&lt;sup>+&lt;/sup> T cells in the spleens of tumor-bearing mice exhibited a stronger anti-tumor activity in vitro than CD39&lt;sup>-&lt;/sup> T cells, but there was no significant difference in the anti-tumor activities between CD39&lt;sup>-&lt;/sup> TILs and CD39&lt;sup>+&lt;/sup> TILs. Moreover, we found that CD39&lt;sup>+&lt;/sup> T cells expressed higher checkpoint molecules and contained a higher proportion of Treg cells than CD39&lt;sup>-&lt;/sup> T cells, suggesting that CD39&lt;sup>+&lt;/sup> T cells may be correlated with an immunosuppressive phenotype. And CD39 expression on T cells could convert pro-inflammatory eATP to immunosuppressive eADO. However, both T cells from the vaccinated-wild-type mice and CD39&lt;sup>-/-&lt;/sup> mice could recognize and eliminate tumor cells in vitro, and adoptive transfer of these T cells resulted in tumor growth inhibition in tumor-bearing mice. In conclusion, our study revealed the divergent functions of CD39&lt;sup>+&lt;/sup> T cells, which were reactive to tumor antigen but exhibited a dysfunctional phenotype.</pubmed_abstract><journal>American journal of cancer research</journal><pagination>585-600</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10915329</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CD39&lt;sup>+&lt;/sup> tumor infiltrating T cells from colorectal cancers exhibit dysfunctional phenotype.</pubmed_title><pmcid>PMC10915329</pmcid><pubmed_authors>Bu Z</pubmed_authors><pubmed_authors>Xia J</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Feng Y</pubmed_authors><pubmed_authors>Lu Z</pubmed_authors><pubmed_authors>Yang P</pubmed_authors><pubmed_authors>Sanderson C</pubmed_authors><pubmed_authors>Xu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD39&lt;sup>+&lt;/sup> tumor infiltrating T cells from colorectal cancers exhibit dysfunctional phenotype.</name><description>Recent studies revealed that CD39 was highly expressed in tumor-specific CD4&lt;sup>+&lt;/sup> tumor infiltrating lymphocytes (TILs). However, the divergent function of CD39&lt;sup>+&lt;/sup> T cells remains to be elucidated in colorectal cancer (CRC). In this study, T cells from CRC patients and tumor-bearing mice were isolated to evaluate the function of CD39 in T cells. We found that CD39 was elevated in intratumoral T cells from CRC patients, and negatively correlated with cytokine secretion capacity. T cell activation induced CD39 expression, and CD39&lt;sup>+&lt;/sup> T cells produced more IFN-γ in response to CRC tumor antigens. In addition, CD39&lt;sup>+&lt;/sup> T cells in the spleens of tumor-bearing mice exhibited a stronger anti-tumor activity in vitro than CD39&lt;sup>-&lt;/sup> T cells, but there was no significant difference in the anti-tumor activities between CD39&lt;sup>-&lt;/sup> TILs and CD39&lt;sup>+&lt;/sup> TILs. Moreover, we found that CD39&lt;sup>+&lt;/sup> T cells expressed higher checkpoint molecules and contained a higher proportion of Treg cells than CD39&lt;sup>-&lt;/sup> T cells, suggesting that CD39&lt;sup>+&lt;/sup> T cells may be correlated with an immunosuppressive phenotype. And CD39 expression on T cells could convert pro-inflammatory eATP to immunosuppressive eADO. However, both T cells from the vaccinated-wild-type mice and CD39&lt;sup>-/-&lt;/sup> mice could recognize and eliminate tumor cells in vitro, and adoptive transfer of these T cells resulted in tumor growth inhibition in tumor-bearing mice. In conclusion, our study revealed the divergent functions of CD39&lt;sup>+&lt;/sup> T cells, which were reactive to tumor antigen but exhibited a dysfunctional phenotype.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-26T03:13:00.886Z</modification><creation>2026-06-26T03:07:13.808Z</creation></dates><accession>S-EPMC10915329</accession><cross_references><pubmed>38455401</pubmed><doi>10.62347/izen3736</doi></cross_references></HashMap>